The final aim of PREPARE is to prepare future treatment trials for ARCAs by facilitating all translational steps from genetic profiling, standardized preclinical trials to registry-inventoried FDA-conform trial ready cohorts. Treatment trials will only consider targeted molecular interventions with a strong pathophysiology rationale.

If you have promising compounds targeting ARCA pathomechanisms which you would like to test in preclinical or clinical trials, please feel free to get in contact with us.